U.S. Residential REITs Stock News

NYSE:NVST
NYSE:NVSTMedical Equipment

Envista Holdings' (NVST) New Buyback: Confident Capital Allocation or Limited Reinvestment Ambition?

Envista Holdings Corporation reported past first-quarter 2026 results with sales of US$705.5 million and net income of US$38.7 million, alongside higher earnings per share from continuing operations versus a year earlier. Alongside these stronger results, Envista completed a prior share repurchase program and approved a new US$300 million buyback running through 2029, underscoring management’s confidence in the business despite tariff and China-related risks. Now we’ll examine how stronger...
NYSE:YUMC
NYSE:YUMCHospitality

A Look At Yum China (YUMC) Valuation After Q1 2026 Results And Ongoing Buybacks

Yum China Holdings (YUMC) has just delivered its first quarter 2026 update, pairing revenue and operating profit growth with fresh details on store expansion, capital returns, and regulatory disclosures that investors can now weigh more closely. See our latest analysis for Yum China Holdings. Despite the first quarter update, Yum China Holdings' share price has moved lower, with a 1 month share price return of 5.75% and a 3 month share price return decline of 17.89%, while the 1 year total...
NYSE:PACS
NYSE:PACSHealthcare

New CFO and Alaska Expansion Might Change The Case For Investing In PACS Group (PACS)

PACS Group, Inc. recently expanded its footprint by acquiring Ridgeway Senior Living in Anchorage, Alaska, along with adjacent land for a planned 150-bed skilled nursing facility, and also set May 11, 2026 as the date it reported its Q1 2026 results. At the same time, the company reshaped its leadership bench by appointing veteran finance executive Carey P. Hendrickson as Chief Financial Officer while co-founder Mark Hancock transitions toward retirement but remains Vice Chairman on the...
NYSE:BBU
NYSE:BBUIndustrials

A Look At Brookfield Business Partners (NYSE:BBU) Valuation After Softer Q1 Earnings And Recent Share Price Pullback

Q1 earnings and dividend decision put Brookfield Business Partners (NYSE:BBU) in focus Brookfield Business Partners (NYSE:BBU) is drawing attention after Brookfield Business Corporation reported first quarter 2026 results with lower sales and net income, alongside a fresh quarterly dividend declaration. For the quarter ended March 31, 2026, Brookfield Business Corporation reported sales of US$6,436 million, compared with US$6,749 million a year earlier, and net income of US$40 million,...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

The Bull Case For IRADIMED (IRMD) Could Change Following Q1 Results And Reaffirmed 2026 Guidance - Learn Why

In early May 2026, IRADIMED CORPORATION reported first-quarter results showing sales of US$21.98 million and net income of US$5.82 million, alongside board approval of a regular US$0.20 per-share quarterly dividend payable on May 29, 2026 to shareholders of record on May 15, 2026. The company also issued earnings guidance for the second quarter and reaffirmed full-year 2026 revenue and GAAP diluted EPS targets, underscoring management’s confidence in its operating outlook. We’ll now...
NYSE:KRG
NYSE:KRGRetail REITs

What Kite Realty Group Trust (KRG)'s 2026 EPS Guidance After Softer Q1 Results Means For Shareholders

Kite Realty Group Trust reported past first-quarter 2026 results with sales of US$198.04 million and net income of US$11.39 million, alongside lower earnings per share than a year earlier. Alongside these softer year-on-year figures, management issued full-year 2026 earnings guidance of US$0.33 to US$0.39 per diluted share, offering fresh insight into expected profitability. We’ll now examine how this updated 2026 earnings guidance reshapes Kite Realty Group Trust’s existing investment...
NasdaqGS:BHF
NasdaqGS:BHFInsurance

Assessing Brighthouse Financial (BHF) Valuation After Recent Share Price Moves And Modest Undervaluation Estimate

Brighthouse Financial (BHF) has been drawing fresh attention after recent share price moves, with the stock closing at US$61.38 and showing mixed returns over the past month and the past 3 months. See our latest analysis for Brighthouse Financial. For context, Brighthouse Financial’s 1-year total shareholder return of 3.28% and 3-year total shareholder return of 51.14% contrast with a share price that is down 4.94% year to date. This suggests momentum has cooled recently after a stronger...
NasdaqGS:TER
NasdaqGS:TERSemiconductor

Why Teradyne (TER) Is Up 6.6% After Surging Q1 Earnings And Fresh Q2 Guidance

Teradyne, Inc. reported first-quarter 2026 results showing sales of US$1,282.49 million and net income of US$398.91 million, with basic earnings per share from continuing operations of US$2.55, and announced a quarterly dividend of US$0.13 per share payable on June 12, 2026 to shareholders of record on May 21, 2026. Alongside this strong year-over-year improvement in profitability, Teradyne also issued second-quarter 2026 guidance calling for revenue of US$1,150 million to US$1,250 million...
NYSE:RXO
NYSE:RXOTransportation

A Look At RXO (RXO) Valuation As AI Freight Gains And Outlook Lift Investor Interest

RXO (RXO) drew fresh attention after reporting first quarter 2026 results, with revenue of US$1.425b and a net loss of US$36m, as management pointed to improving freight trends and expanding AI driven logistics capabilities. See our latest analysis for RXO. RXO's share price has moved sharply around the latest results, with a 1 day share price decline of 5.9% but a 69.4% year to date share price return and a 34.6% 1 year total shareholder return suggesting strong momentum has built over...
NYSE:FUN
NYSE:FUNHospitality

A Look At Six Flags (FUN) Valuation After Strong Q1 Revenue And Attendance Growth

Six Flags Entertainment (FUN) stock recently reacted to first quarter results, as revenue reached US$225.63 million on attendance up 4% and per capita spending up 6%, with net revenue rising 12%. See our latest analysis for Six Flags Entertainment. The Q1 beat on revenue and improving attendance appears to have sparked fresh interest, with the share price up 42.09% year to date and 21.87% over 90 days, although the 1 year total shareholder return is still down 42.28%, pointing to momentum...
NasdaqGS:VSAT
NasdaqGS:VSATCommunications

A Look At Viasat (VSAT) Valuation As New Directors Join Board And Strategic Review Committee

Viasat (VSAT) added two independent directors, Shekar Ayyar and Jinhy Yoon, to its Board and Strategic Review Committee as part of a cooperation agreement with Carronade Capital and aligned investors focused on core assets. See our latest analysis for Viasat. The latest board changes come as momentum in Viasat’s stock remains strong, with the share price at US$70.01 and a 90 day share price return of 55.58%, while the 1 year total shareholder return is very large at around 7x. If this kind of...
NYSE:FNF
NYSE:FNFInsurance

How Investors Are Reacting To Fidelity National Financial (FNF) Earnings Beat, AI Push and New Debt Shelf

In early May 2026, Fidelity National Financial reported first-quarter 2026 results showing higher revenue of US$3,226 million and net income of US$243 million compared with the prior year, affirmed a quarterly dividend of US$0.52 per share for payment on June 30, 2026, and filed a shelf registration for future debt securities offerings. Alongside these developments, the company emphasized expanding AI and technology use to improve title operations and margins while proposing annual director...
NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

Should PROCEPT BioRobotics’ Reaffirmed 2026 Outlook Amid Wider Losses Require Action From PRCT Investors?

In April 2026, PROCEPT BioRobotics Corporation reported first-quarter 2026 results showing sales of US$83.13 million versus US$69.16 million a year earlier, alongside a wider net loss of US$31.64 million and basic loss per share of US$0.56. At the same time, the company reaffirmed its full-year 2026 outlook, including expected revenue of US$390 million to US$410 million and a net loss range of US$78.50 million to US$91.50 million, underlining management’s confidence in its growth plans...
NYSE:EL
NYSE:ELPersonal Products

Estée Lauder (EL) Is Up 6.0% After Major Restructuring And EPS Update Has The Bull Case Changed?

In early May 2026, The Estée Lauder Companies reported third-quarter fiscal 2026 sales of US$3,712 million and net income of US$89 million, narrowed its full-year EPS outlook to US$0.69–US$0.83, flagged a 2% sales headwind for the fourth quarter, affirmed a US$0.35 dividend, and continued addressing legal issues including data-breach and shareholder settlements. At the same time, the company moved ahead with a broad restructuring that includes cutting nearly 20% of its global workforce while...
NYSE:HIMS
NYSE:HIMSHealthcare

Should Hims & Hers Health’s AI and GLP-1 Push Require Action From Hims & Hers Health (HIMS) Investors?

In recent weeks, Hims & Hers Health launched its Labs AI agent to help users interpret biomarker lab results, expanded access to branded GLP-1 weight-loss drugs through partnerships with Novo Nordisk and Eli Lilly, and confirmed upcoming board changes that will reduce its board size to nine directors while retaining its Global Chief Medical Officer. Together, these moves highlight how Hims & Hers is leaning on AI-enabled care and branded obesity treatments to deepen patient engagement and...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

A Look At XPEL (XPEL) Valuation After First Quarter 2026 Earnings Beat And Upbeat Outlook

XPEL (XPEL) stock is back in focus after first quarter 2026 results topped analyst expectations, with revenue of US$117.35 million and earnings per share of US$0.37, along with higher second quarter revenue guidance. See our latest analysis for XPEL. Despite the earnings beat and higher Q2 revenue guidance, XPEL's short term share price momentum has been weak. The stock is down over the past week, quarter, and year to date, even as the 1 year total shareholder return remains positive and...
NasdaqGM:BCAX
NasdaqGM:BCAXBiotechs

Should Bicara’s Wider Q1 Loss and New Institutional Stakes Shift the BCAX Investment Narrative?

Bicara Therapeutics has reported first-quarter 2026 results showing a wider net loss of US$56.21 million, with basic and diluted loss per share from continuing operations at US$0.93, up from US$0.68 a year earlier. At the same time, institutional investors such as FMR LLC and Red Tree have disclosed mid single-digit percentage stakes, highlighting growing professional interest even as losses increase. We’ll now examine how this larger quarterly loss, against Bicara’s earlier growth...
NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones

NewAmsterdam Pharma Company N.V. has reported first-quarter 2026 results, posting US$3.04 million in sales and a net loss of US$48.44 million, while outlining ongoing Phase 3 programs for its lead drug obicetrapib. Investors also heard that an interim analysis of the PREVAIL cardiovascular outcomes trial is planned for late 2026, alongside pending European regulatory decisions and potential initial commercial launches of obicetrapib by Menarini. We will now examine how the planned PREVAIL...
NYSE:SBH
NYSE:SBHSpecialty Retail

Does Strong Q2 Momentum Amid Softer Half-Year Earnings Shift the Bull Case For Sally Beauty (SBH)?

Sally Beauty Holdings, Inc. has released its second-quarter 2026 results, reporting sales of US$903.38 million and net income of US$42.7 million, with both revenue and earnings per share rising compared with the same period a year earlier. While second-quarter performance improved year over year, the company’s net income for the first six months slipped to US$88.25 million, highlighting a contrast between recent quarterly momentum and softer results over the broader half-year period. We’ll...